Zenith Capital Corp. (ZHCLF)

OTCMKTS · Delayed Price · Currency is USD
0.0500
0.00 (0.00%)
Apr 28, 2026, 9:30 AM EST
-50.00%
Market Cap 7.99M
Revenue (ttm) 500.00K
Net Income (ttm) -7.66M
Shares Out 159.73M
EPS (ttm) -0.05
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Average Volume 11,737
Open 0.0500
Previous Close 0.0500
Day's Range 0.0500 - 0.0500
52-Week Range 0.0001 - 0.1900
Beta 687.95
RSI 46.41
Earnings Date Aug 26, 2026

About Zenith Capital

Zenith Capital Corp., a biotechnology investment company, engages in the development of bromodomain inhibitors for the treatment of cancer and other disorders with unmet medical needs. The company’s lead compound ZEN-3694, which is in Phase 2 clinical trial for the treatment of metastatic castration resistant prostate cancer in collaboration with Astellas and Newsoara, as well as advanced or metastatic triple-negative breast cancer in collaboration with Pfizer. It has a research and development collaboration agreement with the National Cancer I... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2013
Country Canada
Stock Exchange OTCMKTS
Ticker Symbol ZHCLF
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.